Comparative Studies of an Orally-active Factor Xa Inhibitor, YM-60828, with other Antithrombotic Agents in a Rat Model of Arterial Thrombosis

Summary We examined the antithrombotic activity of a novel synthetic inhibitor of factor Xa, YM-60828, in an electrically-induced carotid artery thrombosis model in rats. In the first experiment, the antithrombotic activity of YM-60828 after i.v. infusion was compared with those of heparin, darteparin and argatroban. Test drug was administered by i.v. infusion from 30 min before electrical stimulation to the end of the experiment. YM-60828 at 1 mg/kg/h significantly improved patency status, prolonged the time to occlusive thrombus formation and duration of patency. Heparin at 300 U/kg/h also improved these parameters, but were accompanied by a marked increase in systemic coagulation time. In the second experiment, the antithrombotic activity of YM-60828 after oral administration was compared with those of ticlopidine, cilostazol, aspirin, beraprost, ethyl icosapentate and warfarin. Test drug was orally administered to fasted rats 60 min before electrical stimulation. YM-60828 at 30 mg/kg p.o., but not ticlopidine, cilostazol, aspirin, beraprost, ethyl icosapentate or warfarin, significantly reduced the incidence of occlusion and improved carotid arterial patency. These results suggest that YM-60828 may be a promising antithrombotic agent for the treatment and prevention of arterial thrombosis which can be given by oral as well as intravenous administration.

[1]  P. Wong,et al.  Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. , 1996, Thrombosis research.

[2]  H. Büller,et al.  Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. , 1996, Circulation.

[3]  T E Cuddy,et al.  Atrial fibrillation and atrial flutter. , 1996, The Canadian journal of cardiology.

[4]  H. Narita,et al.  Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats. , 1995, Japanese journal of pharmacology.

[5]  H. Ishihara,et al.  DX-9065a, an Orally Active, Specific Inhibitor of Factor Xa, Inhibits Thrombosis without Affecting Bleeding Time in Rats , 1995, Thrombosis and Haemostasis.

[6]  Y. Kiyota,et al.  Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. , 1995, Thrombosis research.

[7]  V. Fuster,et al.  Persistent Thrombin Generation in Humans During Specific Thrombin Inhibition With Hirudin , 1994, Circulation.

[8]  H. Asakura,et al.  Effects of DX-9065a, an Orally Active, Newly Synthesized and Specific Inhibitor of Factor Xa, against Experimental Disseminated Intravascular Coagulation in Rats , 1994, Thrombosis and Haemostasis.

[9]  H. Ishihara,et al.  DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa , 1994, Thrombosis and Haemostasis.

[10]  G. Palareti,et al.  Antithrombotic drugs in peripheral obliterative arterial diseases. , 1994, Haemostasis.

[11]  C. Ehrhardt,et al.  Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. , 1993, Trends in pharmacological sciences.

[12]  B. Francis,et al.  Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. , 1993, Thrombosis research.

[13]  S. Durham,et al.  Effects of Antithrombotic Drugs in a Rat Model of Aspirin-Insensitive Arterial Thrombosis , 1993, Thrombosis and Haemostasis.

[14]  H. Kawano,et al.  Effects of highly purified ethyl all-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on rabbit platelets. , 1993, Biological & pharmaceutical bulletin.

[15]  T. Takenaka,et al.  Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator. , 1993, Japanese journal of pharmacology.

[16]  C. Dunwiddie,et al.  Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[17]  M. D. Freedman.  Oral Anticoagulants: Pharmacodynamics, Clinical Indications and Adverse Effects , 1992, Journal of clinical pharmacology.

[18]  L. Kutcher,et al.  The effect of thrombin inhibition in a rat arterial thrombosis model. , 1991, Thrombosis research.

[19]  T. Kumada,et al.  Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats. , 1991, Thrombosis research.

[20]  J. Hirsh.  Oral anticoagulant drugs. , 1991, The New England journal of medicine.

[21]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[22]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[23]  S. Hanson,et al.  Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin. , 1989, The Journal of laboratory and clinical medicine.

[24]  P. Hogg,et al.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Reisch,et al.  Prevention of Venous Thromboembolism in General, Surgical Patients: Results of a Meta-Analysis , 1989 .

[26]  R. Collins,et al.  Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. , 1988, The New England journal of medicine.

[27]  J. D. Frank,et al.  Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the rat. , 1988, Thrombosis research.

[28]  T. Hirano,et al.  The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. , 1988, Japanese journal of pharmacology.

[29]  R. Kikumoto,et al.  Effect of a Synthetic Thrombin Inhibitor MCI-9038 on Experimental Models of Disseminated Intravascular Coagulation in Rabbits , 1987, Thrombosis and Haemostasis.

[30]  D. Bergqvist,et al.  The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. , 1985, Thrombosis research.

[31]  C. Mattsson,et al.  Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. , 1982, Thrombosis research.

[32]  B. Warren,et al.  Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis. , 1978, Haemostasis.

[33]  M. Mant,et al.  HÆMORRHAGIC COMPLICATIONS OF HEPARIN THERAPY , 1977, The Lancet.

[34]  R. O'Reilly.  The pharmacodynamics of the oral anticoagulant drugs. , 1974, Progress in hemostasis and thrombosis.

[35]  R. Rosenberg,et al.  Anticoagulant Action of Heparin , 1973, Nature.

[36]  R. Biggs,et al.  Standardization of the one-stage prothrombin time test for the control of anticoagulant therapy: availability and use of thromboplastin reference preparations. , 1971, Thrombosis et diathesis haemorrhagica.